CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Lenz Therapeutics Reports 110,000 VIZZ Prescriptions Since Launch

By Public Technologies
  • Lenz Therapeutics reported 50% quarter-over-quarter growth in Q3 2026, with VIZZ reaching 110,000 total prescriptions since launch.
  • Cash totaled approximately $197 million as of Q3 2026.
  • Eleven international regulatory applications are under review, with the first approval anticipated as early as Q4 2026.
  • Up to five international regulatory approvals are expected by the end of 2027.
  • VIZZ has eight granted US patents extending up to 2044, with US new chemical entity regulatory exclusivity through 2030.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lenz Therapeutics Inc. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk